Pneumoccoccal Conjugate Vaccine Gets FDA Priority Review Status

September 1999
Biotech Business;Sep99, Vol. 12 Issue 9, p1
Trade Publication
Reports that Wyeth Lederle Vaccine's pneumococcal conjugate vaccine was granted priority review status by the United States Food and Drug Administration. Illnesses caused by the pneumococcus bacteria; Disabilities in children caused by meningitis; Number of cases of pneumococcal meningitis and cases of bacteremia among children in the United States each year.


Related Articles

  • Legacy Products and Process Monitoring Raise Concern in Revised Process Validation Guidance.  // BioPharm International;Apr2009, Vol. 22 Issue 4, p14 

    The article focuses on the concerns raised by pharmaceutical organizations in the U.S. over the revision of the 1987 Process Validation Guidance of the U.S. Food and Drug Administration. It notes that Baxter Co. and Wyeth Co, were among the 45 organizations which asked the FDA for the...

  • Prevnar 13 approved.  // Monthly Prescribing Reference;Mar2010, Vol. 26 Issue 3, pA19 

    The article reports on the approval of Prevnar 13, a pneumococcal 13-valent conjugate vaccine from Wyeth, for the prevention of invasive pneumococcal disease and otitis media in children aged six weeks to five years.

  • Law and the Public's Health. Rosenbaum, Sara; David, Stephanie // Public Health Reports;May/Jun2010, Vol. 125 Issue 3, p494 

    The article discusses a Supreme court case of Wyeth v. Levine in the U.S. on misleading drug labeling. The Supreme Court rejected the argument on implied conflict preemption of Wyeth and finds that Wyeth could have strengthened the Phenergan drug labeling without the Food and Drug...

  • Safety labeling updates & new warnings.  // Formulary;Oct2008, Vol. 43 Issue 10, p381 

    The article reports on the notification of the Food and Drug Administration (FDA) to change the labeling of the drugs adalimumab, certolizumab pegol, etanercept and infliximab. Among the manufacturers who received the warning are Abott, UCB, Amgen/Wyeth and Centocor. The change, according to the...

  • WALL STREET CHOICE.  // Medical Marketing & Media;Jun2007, Vol. 42 Issue 6, p34 

    The article reports that Wyeth is anticipating the extension of its review of its antidepressant drug Pristiq by the Food and Drug Administration (FDA) in the U.S. It is noted that Wyeth asserts the inclusion of the low dose data will enhance the profile of Pristiq in launching the vasomotor...

  • New delivery system approved for ReFacto.  // Drug Topics;9/27/2004, Vol. 148 Issue 18, p8 

    This article states that the United States Food and Drug Administration approved Wyeth's ReFacto Antihemophilic Factor R2 Kit needle-less reconstitution device.

  • REPORTER'S NOTEBOOK.  // Drug Store News;12/19/2005, Vol. 27 Issue 17, p83 

    The article reports developments in pharmaceutical industry in the U.S. Wyeth has received a panic disorder indication for its antidepressant Effexor XR from the Food and Drug Administration (FDA). The safety of Roche Laboratories' antiviral Tamiflu in children was affirmed by an FDA advisory...

  • Rules may restrict clinical data claims. Iskowitz, Marc // Medical Marketing & Media;Mar2007, Vol. 42 Issue 3, p9 

    The article focuses on the rules that limits the number of clinical data claims in the U.S. Geoff Levitt, vice president and chief counsel for Wyeth Inc., states that some companies use clinical data to get information specifically on unapproved clinical studies. The Food and Drug Administration...

  • Wyeth shops FluMist DTC acc't. Sanders, Lisa; Goetzl, David // Advertising Age;9/2/2002, Vol. 73 Issue 35, p3 

    The article deals with the review being conducted by Wyeth on a direct-to-consumer (DTC) account for a flu vaccine, FluMist, that could replace the annual flu shot for some people. But a DTC launch that carries high expectations can spend in the $40 million to 50 million range or more. Agencies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics